Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Long- and Short-acting Diuretics in Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of heart failure based on a slight modification of the Framingham criteria as previously described within 6 months before the entry~* Current status of heart failure is NYHA II or III.~* Currently, loop diuretic(s) is (are) administered.~* No change in baseline therapy and symptoms of heart failure within a month~Exclusion Criteria:~* Current symptomatic hypotension~* Hypertension that has not been controlled to the satisfaction of the investigator~* Hemodynamically significant (in the investigators opinion) LV outflow tract obstruction (due to either aortic stenosis or ventricular hypertrophy)~* Acute coronary syndrome~* Primary pulmonary hypertension or pulmonary hypertension not due to LV dysfunction~* Serious cerebrovascular disease~* Acute myocardial infarction within the last 3 months~* Patients who require intravenous inotropes~* Cerebrovascular accident within the last 3 months~* Percutaneous coronary intervention or open heart surgery within the last 3 months~* On the waiting list for percutaneous coronary intervention or open heart surgery~* Serum creatinine \> 2.5 mg/dl~* Serious liver disease~* Any change in cardiovascular drug therapy within a month prior to randomization~* History of chronic obstructive pulmonary disease or restrictive lung disease~* Diabetes mellitus that has not been well controlled (fasting blood glucose\>200 mg/dl、HbA1c \> 8%)~* Any life-threatening acute disease~* Patients with implantable cardiac defibrillator~* Other diseases likely to cause death or serious disability during the period of the study~* Patients unable to walk without personal aid

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Patients with chronic heart failure with NYHA II or III are given furosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with furosemide 20-40 mg/day, without a placebo run-in period. The dose of each diuretic was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.
- B (Type: ACTIVE_COMPARATOR): Patients with chronic heart failure with NYHA II or III are given azosemide.Patients discontinued taking previous loop diuretic(s) and were directly rolled over to the arm with azosemide 30-60 mg/day without a placebo run-in period. The dose of azosemide was appropriately adjusted according to symptoms of each patient, and patients were maintained for the rest of the study. Thereafter, patients were reviewed every 2 to 8 weeks. The planned minimum follow-up period for each patient was 2 years, and electrocardiography, chest X-ray and blood sample were conducted at the study entry and every 12 months after the randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).